3篇
您的检索式：作者名="ZENG ChengWu"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq显示文摘Previous analyses have reported that the human monocytic cell line THP1 can be differentiated into cells with macrophage-like characteristics by phorbol 12-myristate 13-acetate(PMA). However, little is known about the mechanism responsible for regulating this differentiation process. Here, we performed high-throughput RNA-Seq analysis to investigate the genes differently expressed in THP1 cells treated with and without PMA and examined those that may be responsible for the PMA-induced differentiation of monocytes into macrophages. We found 3,000 genes to be differentially expressed after PMA treatment. Gene ontology analysis revealed that genes related to cellular processes and regulation of biological processes were significantly enriched. KEGG analysis also demonstrated that the differentially expressed genes(DEGs) were significantly enriched in the PI3K/AKT signaling pathway and phagosome pathway. Importantly, we reveal an important role of the PI3K/AKT pathway in PMA-induced THP1 cell differentiation. The identified DEGs and pathways may facilitate further study of the detailed molecular mechanisms of THP1 differentiation. Thus, our results provide numerous potential therapeutic targets for modulation of the differentiation of this disease. | ZENG ChengWu WANG WenTao YU XiBao YANG LiJian CHEN ShaoHua LI YangQiu | 2015 | Science China(Life Sciences)2015，58，12： | 7 |
| 2 | The importance of genomic predictors for clinical outcome of hematological malignancies显示文摘Hematological malignancy is 1 of the top 10 malignant diseases with regards to cancer patient morbidity and mortality.^(1) Although hematopoietic stem cell transplantation,chemotherapy,and targeted therapy have made great progress in recent years,patients with hematological malignancies still have adverse clinical outcomes,particularly elderly patients.^(2,3) Therefore,it is necessary to explore for an optimal prediction model to evaluate the clinical outcome,which is important for devising a therapeutic strategy for hematological diseases. | Cunte Chen Chengwu Zeng Yangqiu Li | 2021 | Blood Science2021，3，3： | 0 |
| 3 | Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis显示文摘Regulated cell death(RCD)is essential for maintaining cell homeostasis and preventing diseases.Besides classical apoptosis,several novel nonapoptotic forms of RCD including NETosis,pyroptosis,ferroptosis,and cuproptosis have been reported and are increasingly being implicated in various cancers and inflammation.Disulfiram(DSF),an aldehyde dehydrogenase inhibitor,has been used clinically for decades as an anti-alcoholic drug.New studies have shown that DSF possesses potent anti-inflammatory and anti-cancer effects by regulating these new types of RCD.Here,we summarize the mechanisms and discuss the potential application of DSF in the treatment of cancers and inflammatory diseases. | Dingrui Nie Cunte Chen Yangqiu Li Chengwu Zeng | 2022 | Blood Science2022，4，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员